Download PDF
Z Gastroenterol 2006; 44(1): 43-49
DOI: 10.1055/s-2005-858932
Übersicht

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

Therapie des hepatozellulären Karzinoms

Treatment of Hepatocellular CarcinomaT. F. Greten1 , H. E. Blum2 , M. P. Manns1 , M. Geissler2, 3
  • 1Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
  • 2Medizinische Klinik II, Universität Freiburg
  • 3Klinik für Onkologie, Gastroenterologie und Allgemeine Innere Medizin, Städtische Kliniken Esslingen a. N.
Further Information

Publication History

Manuskript eingetroffen: 24.8.2005

Manuskript akzeptiert: 10.11.2005

Publication Date:
05 January 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das hepatozelluläre Karzinom (HCC) ist weltweit einer der häufigsten malignen Tumoren mit steigender Inzidenz auch in westlichen Ländern. Das HCC wird typischerweise erst relativ spät im Verlauf diagnostiziert und bis auf wenige Ausnahmen ist die Prognose ungünstig. Potenziell kurative Therapieansätze sind die Tumorresektion und in ausgewählten Fällen die Lebertransplantation. Diese chirurgischen Verfahren kommen aber aufgrund des Tumorstadiums oder der Leberfunktion für einen Großteil der Patienten nicht infrage. Weitere nichtchirurgische Therapieverfahren wie Radiofrequenzthermo- und Kryoablation, Alkohol- oder Säureinjektionen, transarterielle Chemoembolisationen, Strahlentherapie und systemische Chemotherapie können einzeln oder in Kombination in den verschiedenen Stadien der Erkrankung eingesetzt werden, um eine Verlängerung des (rezidivfreien) Überlebens und in wenigen Fällen auch eine Heilung zu erzielen.

Abstract

Hepatocellular carcinoma is one of the most common cancers worldwide. The incidence of this disease is also increasing in the Western world. Typically, HCC is diagnosed when patients have already reached an advanced stage of the disease and the prognosis is poor. Potentially curative treatment options include surgical resection or liver transplantation and can be offered to patients with adequate liver function and tumour stage. Other non-surgical treatment options such as radiofrequency ablation, cryoablation, ethanol or acetic acid injection, transarteriel chemoembolisation radiation therapy and systemic chemotherapy can be offered either alone or in combination to selected groups of patients. These treatments can improve (tumour-free) survival and in a few cases even cure the patient.

Schlüsselwörter

Leber - Chemotherapie - Krebs

Key words

Liver - chemotherapy - cancer

Reference

  • 1 Parkin D M, Bray F, Ferlay J. et al . Estimating the world cancer burden: Globocan 2000.  Int J Cancer. 2001;  44 153-156
    PubMedGoogle Scholar
  • 2 Deuffic S, Poynard T, Buffat L. et al . Trends in primary liver cancer.  Lancet. 1998;  44 214-215
    PubMedGoogle Scholar
  • 3 El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States.  N Engl J Med. 1999;  44 745-750
    PubMedGoogle Scholar
  • 4 Fattovich G, Giustina G, Degos F. et al . Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.  Gastroenterology. 1997;  44 463-472
    PubMedGoogle Scholar
  • 5 Talwalkar J A, Gores G J. Diagnosis and staging of hepatocellular carcinoma.  Gastroenterology. 2004;  44 S126-S132
    PubMedGoogle Scholar
  • 6 Marrero J A, Fontana R J, Barrat A. et al . Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort.  Hepatology. 2005;  44 707-715
    PubMedGoogle Scholar
  • 7 Okuda K, Ohtsuki T, Obata H. et al . Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients.  Cancer. 1985;  44 918-928
    PubMedGoogle Scholar
  • 8 Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators.  Hepatology. 2000;  44 840-845
    PubMedGoogle Scholar
  • 9 Llovet J M, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.  Liver Transpl. 2004;  44 S115-S120
    PubMedGoogle Scholar
  • 10 Kudo M, Chung H, Haji S. et al . Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.  Hepatology. 2004;  44 1396-1405
    PubMedGoogle Scholar
  • 11 Mazzaferro V, Regalia E, Doci R. et al . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.  N Engl J Med. 1996;  44 693-699
    PubMedGoogle Scholar
  • 12 Villa E, Colantoni A, Camma C. et al . Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems.  J Clin Oncol. 2003;  44 441-446
    PubMedGoogle Scholar
  • 13 Schwartz M. Liver transplantation for hepatocellular carcinoma.  Gastroenterology. 2004;  44 S268-S276
    PubMedGoogle Scholar
  • 14 Schlitt H J, Neipp M, Weimann A. et al . Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation.  J Clin Oncol. 1999;  44 324-331
    PubMedGoogle Scholar
  • 15 Jonas S, Bechstein W O, Steinmuller T. et al . Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.  Hepatology. 2001;  44 1080-1086
    PubMedGoogle Scholar
  • 16 Shetty K, Timmins K, Brensinger C. et al . Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome.  Liver Transpl. 2004;  44 911-918
    PubMedGoogle Scholar
  • 17 Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70s6 k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells.  Cancer Res. 1996;  44 3895-3897
    PubMedGoogle Scholar
  • 18 Bruix J, Castells A, Bosch J. et al . Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.  Gastroenterology. 1996;  44 1018-1022
    PubMedGoogle Scholar
  • 19 Jaeck D, Bachellier P, Oussoultzoglou E. et al . Surgical resection of hepatocellular carcinoma. Post-operative outcome and long-term results in Europe: an overview.  Liver Transpl. 2004;  44 S58-S63
    PubMedGoogle Scholar
  • 20 Llovet J M, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.  Hepatology. 1999;  44 1434-1440
    PubMedGoogle Scholar
  • 21 Schwartz J D, Schwartz M, Mandeli J. et al . Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.  Lancet Oncol. 2002;  44 593-603
    PubMedGoogle Scholar
  • 22 Lencioni R, Cioni D, Crocetti L. et al . Percutaneous ablation of hepatocellular carcinom: a state-of-the-art.  Liver Transpl. 2004;  44 S91-S97
    PubMedGoogle Scholar
  • 23 Omata M, Tateishi R, Yoshida H. et al . Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation.  Gastroenterology. 2004;  44 S159-S166
    PubMedGoogle Scholar
  • 24 Lencioni R, Cioni D, Crocetti L. et al . Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation.  Radiology. 2005;  44 961-967
    PubMedGoogle Scholar
  • 25 Beaugrand M, N’Kontchou G, Seror O. et al . Local/regional and systemic treatments of hepatocellular carcinoma.  Semin Liver Dis. 2005;  44 201-211
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Livraghi T, Giorgio A, Marin G. et al . Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection.  Radiology. 1995;  44 101-108
    PubMedGoogle Scholar
  • 27 Allgaier H P, Deibert P, Olschewski M. et al . Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection-a single-center analysis including 132 patients.  Int J Cancer. 1998;  44 601-605
    PubMedGoogle Scholar
  • 28 Livraghi T, Benedini V, Lazzaroni S. et al . Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma.  Cancer. 1998;  44 48-57
    PubMedGoogle Scholar
  • 29 Lin S M, Lin C J, Lin C C. et al . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm.  Gastroenterology. 2004;  44 1714-1723
    PubMedGoogle Scholar
  • 30 Sala M, Llovet J M, Vilana R. et al . Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.  Hepatology. 2004;  44 1352-1360
    PubMedGoogle Scholar
  • 31 Lencioni R A, Allgaier H P, Cioni D. et al . Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.  Radiology. 2003;  44 235-240
    PubMedGoogle Scholar
  • 32 Lin S M, Lin C J, Lin C C. et al . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less.  Gut. 2005;  44 1151-1156
    PubMedGoogle Scholar
  • 33 Lo C M, Ngan H, Tso W K. et al . Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.  Hepatology. 2002;  44 1164-1171
    PubMedGoogle Scholar
  • 34 Llovet J M, Real M I, Montana X. et al . Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.  Lancet. 2002;  44 1734-1739
    PubMedGoogle Scholar
  • 35 Kawai S, Tani M, Okamura J. et al . Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma - a comparison between L-TAE with farmorubicin and L-TAE with adriamycin: preliminary results (second cooperative study). Cooperative Study Group for Liver Cancer Treatment of Japan.  Cancer Chemother Pharmacol. 1994;  44 S97-S102
    PubMedGoogle Scholar
  • 36 Bruix J, Sala M, Llovet J M. Chemoembolization for hepatocellular carcinoma.  Gastroenterology. 2004;  44 S179-S188
    PubMedGoogle Scholar
  • 37 A c omparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire.  N Engl J Med. 1995;  44 1256-1261
    PubMedGoogle Scholar
  • 38 Fuss M, Salter B J, Herman T S. et al . External beam radiation therapy for hepatocellular carcinoma: potential of intensity-modulated and image-guided radiation therapy.  Gastroenterology. 2004;  44 S206-S217
    PubMedGoogle Scholar
  • 39 Seong J, Keum K C, Han K H. et al . Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma.  Int J Radiat Oncol Biol Phys. 1999;  44 393-397
    PubMedGoogle Scholar
  • 40 De Ruyck K, Lambert B, Bacher K. et al . Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.  J Nucl Med. 2004;  44 612-618
    PubMedGoogle Scholar
  • 41 Kennedy A S, Nutting C, Coldwell D. et al . Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers.  Int J Radiat Oncol Biol Phys. 2004;  44 1552-1563
    PubMedGoogle Scholar
  • 42 Ganne-Carrie N, Trinchet J C. Systemic treatment of hepatocellular carcinoma.  Eur J Gastroenterol Hepatol. 2004;  44 275-281
    PubMedGoogle Scholar
  • 43 Schachschal G, Lochs H, Plauth M. Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monotherapy in hepatocellular carcinoma.  Eur J Gastroenterol Hepatol. 2000;  44 281-284
    PubMedGoogle Scholar
  • 44 Kubicka S, Rudolph K L, Tietze M K. et al . Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.  Hepatogastroenterology. 2001;  44 783-789
    PubMedGoogle Scholar
  • 45 Lai C L, Wu P C, Chan G C. et al . Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial.  Cancer. 1988;  44 479-483
    PubMedGoogle Scholar
  • 46 Thomas M B, Zhu A X. Hepatocellular carcinoma: the need for progress.  J Clin Oncol. 2005;  44 2892-2899
    PubMedGoogle Scholar
  • 47 Patt Y Z, Hassan M M, Lozano R D. et al . Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2 b for treatment of hepatocellular carcinoma.  J Clin Oncol. 2003;  44 421-427
    PubMedGoogle Scholar
  • 48 Stuart K, Tessitore J, Rudy J. et al . A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma.  Cancer. 1999;  44 410-414
    PubMedGoogle Scholar
  • 49 Barbare J C, Bouche O, Bonnetain F. et al . Randomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma.  J Clin Oncol. 2005;  44 4338-4346
    PubMedGoogle Scholar
  • 50 Nowak A K, Chow P K, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review.  Eur J Cancer. 2004;  44 1474-1484
    PubMedGoogle Scholar
  • 51 Kouroumalis E, Skordilis P, Thermos K. et al . Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.  Gut. 1998;  44 442-447
    PubMedGoogle Scholar
  • 52 Yuen M F, Poon R T, Lai C L. et al . A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.  Hepatology. 2002;  44 687-691
    PubMedGoogle Scholar
  • 53 Allgaier H P, Becker G, Olschewski M. et al . Octreotide treatment in patients with advanced hepatocellular carcinoma: First results of the randomized placebo-controlled double-blind HECTOR trial.  Hepatology. 2003;  44 760A
    PubMedGoogle Scholar
  • 54 Patt Y Z, Hassan M M, Lozano R D. et al . Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.  Cancer. 2005;  44 749-755
    PubMedGoogle Scholar
  • 55 Llovet J M, Sala M, Castells L. et al . Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma.  Hepatology. 2000;  44 54-58
    PubMedGoogle Scholar
  • 56 Kawata S, Yamasaki E, Nagase T. et al . Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.  Br J Cancer. 2001;  44 886-891
    PubMedGoogle Scholar
  • 57 Butterfield L H. Immunotherapeutic strategies for hepatocellular carcinoma.  Gastroenterology. 2004;  44 S232-S241
    PubMedGoogle Scholar
  • 58 Wada Y, Nakashima O, Kutami R. et al . Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration.  Hepatology. 1998;  44 407-414
    PubMedGoogle Scholar
  • 59 Takayama T, Sekine T, Makuuchi M. et al . Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.  Lancet. 2000;  44 802-807
    PubMedGoogle Scholar
  • 60 Greten T F. Antibody therapy for the treatment of colon cancer.  Z Gastroenterol. 2004;  44 1413-1415
    Article in Thieme ConnectPubMedGoogle Scholar
  • 61 Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma.  Lancet. 2003;  44 1907-1917
    PubMedGoogle Scholar

PD Dr. Tim F. Greten

Abt. Gastroenterologie, Hepatologie und Endoskrinologie, Medizinische Hochschule Hannover

Carl-Neuberg-Str. 1

30625 Hannover

Email: greten.tim@mh-hannover.de